Factor 8 Gene Roctavian denied due to quantity / dose limits by Cigna?

Cigna's specific coverage criteria for factor 8 gene roctavian are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Limits the Quantity of Roctavian — and Why You Can Appeal

Roctavian (valoctocogene roxaparvovec) is a one-time gene therapy for adults with severe hemophilia A who have no pre-existing immunity to its delivery vector. Because it is administered as a single infusion, Cigna's quantity limit typically restricts coverage to that single lifetime dose. Denials under this category most commonly arise when a claim is submitted in a way that appears to request re-dosing, or when administrative coding does not clearly align with the approved single-administration intent of the therapy.

## Why This Denial Is Appealable

A quantity-limit denial is not a determination that the therapy is medically inappropriate for your patient — it is a utilization-management decision. If the denial reflects a coding or submission error, it can often be corrected on reconsideration without a formal appeal. If the plan is applying a limit that is stricter than what is medically appropriate for this single-administration product, that constitutes an unreasonable restriction subject to challenge.

## Federal Appeal Framework

• ERISA §503 (self-funded plans): Requires a full-and-fair review. You have 180 days from the denial notice to file an internal appeal.
• ACA §2719 (fully-insured and non-grandfathered plans): After exhausting internal appeals, you have the right to an independent external review, typically within four months of the final internal denial.
• Expedited review: If a standard timeline would seriously jeopardize the patient's health or ability to regain maximum function, request expedited review — decisions are generally required within 72 hours internally and 72 hours externally.

## Concrete Appeal Steps and Timeline

1. Obtain the written denial notice — confirm the exact quantity-limit rationale cited. 2. Request Cigna's complete coverage policy for Roctavian, including the quantity-limit provision. 3. File the internal appeal within 180 days (or sooner — Cigna typically sets its own shorter window). 4. If denied internally, file for external independent review within four months of the final denial.

## Documentation to Gather

• Diagnosis confirmation: Genetic or assay-confirmed severe hemophilia A diagnosis from the treating hematologist.
• Treatment history: Comprehensive record of prior factor-replacement therapy with dates, regimens, and outcomes.
• Vector immunity testing: Documentation of pre-treatment AAV antibody titer testing and results confirming eligibility per the FDA-approved prescribing label.
• Clinical severity: Bleeding frequency logs, annualized bleed rate, joint damage documentation.
• Prescriber letter: A detailed medical-necessity letter from the treating hematologist explaining why this patient meets every criterion in the FDA-approved label and Cigna's own published coverage policy.

## Criteria-Mapping Structure

For each requirement listed in (a) the FDA-approved Roctavian prescribing information and (b) Cigna's published coverage policy, create a side-by-side table: copy the requirement verbatim on the left, and cite the specific chart document and date that satisfies it on the right. This structured mapping is the single most persuasive element of a successful appeal for a gene therapy at this price tier.